Literature DB >> 15593093

Heterogeneity testing in meta-analysis of genome searches.

Elias Zintzaras1, John P A Ioannidis.   

Abstract

Genome searches for identifying susceptibility loci for the same complex disease often give inconclusive or inconsistent results. Genome Search Meta-analysis (GSMA) is an established non-parametric method to identify genetic regions that rank high on average in terms of linkage statistics (e.g., lod scores) across studies. Meta-analysis typically aims not only to obtain average estimates, but also to quantify heterogeneity. However, heterogeneity testing between studies included in GSMA has not been developed yet. Heterogeneity may be produced by differences in study designs, study populations, and chance, and the extent of heterogeneity might influence the conclusions of a meta-analysis. Here, we propose and explore metrics that indicate the extent of heterogeneity for specific loci in GSMA based on Monte Carlo permutation tests. We have also developed software that performs both the GSMA and the heterogeneity testing. To illustrate the concept, the proposed methodology was applied to published data from meta-analyses of rheumatoid arthritis (4 scans) and schizophrenia (20 scans). In the first meta-analysis, we identified 11 bins with statistically low heterogeneity and 8 with statistically high heterogeneity. The respective numbers were 9 and 6 for the schizophrenia meta-analysis. For rheumatoid arthritis, bins 6.2 (the HLA region that is a well-documented susceptibility locus for the disease) and 16.3 (16q12.2-q23.1) had both high average ranks and low between-study heterogeneity. For schizophrenia, this was seen for bin 3.2 (3p25.3-p22.1) and heterogeneity was still significantly low after adjusting for its high average rank. Concordance was high between the proposed metrics and between weighted and unweighted analyses. Data from genome searches should be synthesized and interpreted considering both average ranks and heterogeneity between studies. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15593093     DOI: 10.1002/gepi.20048

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  311 in total

Review 1.  Association between cadherin-17 expression and pathological characteristics of gastric cancer: a meta-analysis.

Authors:  Zi-Wen Long; Meng-Long Zhou; Jing-Wei Fu; Xian-Qun Chu; Ya-Nong Wang
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Association of methylenetetrahydrofolate reductase (MTHFR) polymorphisms with genetic susceptibility to gastric cancer: a meta-analysis.

Authors:  Elias Zintzaras
Journal:  J Hum Genet       Date:  2006-06-07       Impact factor: 3.172

3.  Heterogeneity-based genome search meta-analysis for preeclampsia.

Authors:  Elias Zintzaras; Georgios Kitsios; Gavan A Harrison; Hannele Laivuori; Katja Kivinen; Juha Kere; Ioannis Messinis; Ioannis Stefanidis; John P A Ioannidis
Journal:  Hum Genet       Date:  2006-07-26       Impact factor: 4.132

4.  Meta-analysis of genome-wide scans provides evidence for sex- and site-specific regulation of bone mass.

Authors:  John Pa Ioannidis; Mandy Y Ng; Pak C Sham; Elias Zintzaras; Cathryn M Lewis; Hong-Wen Deng; Michael J Econs; David Karasik; Marcella Devoto; Candace M Kammerer; Tim Spector; Toby Andrew; L Adrienne Cupples; Emma L Duncan; Tatiana Foroud; Douglas P Kiel; Daniel Koller; Bente Langdahl; Braxton D Mitchell; Munro Peacock; Robert Recker; Hui Shen; Katia Sol-Church; Loretta D Spotila; Andre G Uitterlinden; Scott G Wilson; Annie Wc Kung; Stuart H Ralston
Journal:  J Bone Miner Res       Date:  2007-02       Impact factor: 6.741

5.  Estrogen receptor alpha gene polymorphisms and risk of prostate cancer: a meta-analysis involving 18 studies.

Authors:  Zhenwei Gu; Gang Wang; Weiguo Chen
Journal:  Tumour Biol       Date:  2014-03-01

6.  Retraction. rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: a meta-analysis.

Authors:  Ming-Yi Lv; Shu-Ling Deng; Xiao-Feng Long
Journal:  Br J Clin Pharmacol       Date:  2015-11-28       Impact factor: 4.335

Review 7.  Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.

Authors:  Wei Xu; Yang Gong; Meng Kuang; Peng Wu; Chunxiang Cao; Jinfei Chen; Cuiju Tang
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

8.  Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma.

Authors:  Rong-Rong Song; Xiao-Lin Gu
Journal:  Tumour Biol       Date:  2014-12-11

9.  CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression.

Authors:  Bao-Sheng Wang; Zhen Liu; Wei-Xue Xu; Shao-Long Sun
Journal:  Tumour Biol       Date:  2013-04-13

10.  The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses.

Authors:  Neerav Monga; Amyn Sayani; Daniel A Rubinger; Timothy H Wilson; Zhen Su
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.